Who we are
Vibalogics is a global contract development and manufacturing organization (CDMO) offering process and analytical development, manufacturing, testing, and fill-finish services to innovators developing revolutionary virotherapy products.
LEADING THE VIROTHERAPY CDMO MARKET
Experience a unique understanding of virotherapy
We are an ambitious partner with a vision of leading the virotherapy CDMO market by pioneering efficient, economically viable, and GMP compliant manufacture of complex oncolytic viruses, viral vector gene therapies and vaccines, by enabling our customers to deliver transformational products to patients worldwide.
Our industry-leading viral expertise supports your successful progress along the way and helps mitigate challenges frequently seen in this emerging segment of industry, and our comprehensive services support both clinical- and commercial-capability from initial technical transfer, GMP drug substance and drug product manufacture, to quality control batch release facilitating overall speed and security of our customers product supply chain.
Partner with us and you will experience a transparent and consultative partnership. Our ethos of flexibility and open communication provides our customers with the resourceful and adaptable strategies they need to ensure projects are completed successfully, on budget and on time.
Quality infrastructure, continuous investment
Following a 15-year track record in virotherapy manufacturing, in May 2019, Vibalogics was acquired by Ampersand Capital Partners, a private capital firm specializing in investments in the healthcare sector. Investment and continued re-investment annually into our business has played an important part in our growth strategy including:
- Construction of the Boxborough, MA Headquarters for early-to late-phase and commercial virotherapy manufacturing services
- Expansion of our Cuxhaven, Germany for added capacity for Phase 1-2 virotherapy manufacturing services